IDEAYA Biosciences Inc IDYA

Healthcare Biotechnology

IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates are darovasertib (IDE196), IDE397, IDE161 and GSK101 (Pol Theta Helicase). IDE196, a small molecule protein kinase C (PKC), inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397, is its small molecule methionine adenosyltransferase 2a (MAT2A), inhibitor. IDE161, is its small molecule poly (ADP-ribose) glycohydrolase (PARG), inhibitor. IDE196 is its clinical-stage PKC inhibitor that the Company is evaluating as a synthetic lethal combination therapy. IDE397, a MAT2A inhibitor for patients with solid tumors having MTAP deletions. IDE161 is its clinical-stage, potent and selective small molecule inhibitor of PARG for patients having tumors with defined biomarkers based on genetic mutations and/or molecular signatures.

NDAQ:IDYA - Post by User

IDEAYA Biosciences Inc

<< Previous

Bullboard Posts

Next >>

(302)
•••

Post by whytestockson Jul 10, 2024 6:00pm

73 Views

Post# 36127295

Outperform Recommendation Issued On IDYA By RBC Capital

News; $IDYA Outperform Recommendation Issued On IDYA By RBC Capital2024-07-10 16:15:02 ET RBC Capital analyst issues OUTPERFORM recommendation for IDYA on July 10, 2024 02:51PM ET. The previous analyst recommendation was Outperform. IDYA was trading at $37.33 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...IDYA - Outperform Recommendation Issued On IDYA By RBC Capital

<< Previous

Bullboard Posts

Next >>

Elon Musk sued by SEC over Twitter stock purchases